文献速递前列腺增生与排尿功能障碍

膀胱内灌注OnabotulinumtoxinA治疗伴尿失禁的难治性膀胱过度活动症

Intravesical Instillation of OnabotulinumtoxinA in the Treatment of Refractory Overactive Bladder in Participants with Urinary Incontinence.
PubMed 文献 · J Urol · 2022-07-05

本试验在对抗胆碱能药物难治或不耐受的伴急迫性尿失禁的膀胱过度活动症成人中,评估膀胱内灌注OnabotulinumtoxinA+水凝胶混合物的疗效与安全性。第2阶段随机分配至OnabotulinumtoxinA 100、300、400或500 U或安慰剂组。第12周时,尿失禁发作次数变化在安慰剂组为-2.72,在治疗组为-0.89至-1.85;任何疗效终点均未观察到与安慰剂的差异。治疗中出现的不良事件比例组间相似,无症状性菌尿最高(6.7%-15.5%);无尿潴留或排尿后残余尿量升高报告。

要点

  • 膀胱内灌注OnabotulinumtoxinA+水凝胶混合物耐受性良好,但未优于安慰剂。
  • 第12周尿失禁发作次数变化:安慰剂组-2.72,治疗组-0.89至-1.85。
  • 治疗中出现的不良事件比例组间相似,无症状性菌尿最高(6.7%-15.5%)。

核心结论

  • 膀胱内灌注OnabotulinumtoxinA+水凝胶混合物治疗难治性膀胱过度活动症耐受性良好,但未显示优于安慰剂。

研究设计与样本

  • 第1阶段安全性审查后,第2阶段随机分配参与者至OnabotulinumtoxinA 100、300、400或500 U或安慰剂组,均加水凝胶混合物。

主要发现

  • 第12周尿失禁发作次数变化:安慰剂组-2.72,OnabotulinumtoxinA+水凝胶治疗组-0.89至-1.85。
  • 任何疗效终点均未观察到与安慰剂的差异。
  • 治疗中出现的不良事件比例组间相似,无症状性菌尿最高(6.7%-15.5%)。
  • 无尿潴留或排尿后残余尿量升高的报告。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Intradetrusor injections of onabotulinumtoxinA are efficacious for the treatment of overactive bladder with urgency urinary incontinence in adults refractory to or intolerant of anticholinergics. Delivery of onabotulinumtoxinA via instillation would reduce the need for intradetrusor injections. The objective of this trial was to assess the efficacy and safety of intravesical instillation of an onabotulinumtoxinA + hydrogel admixture. MATERIALS AND METHODS: After review of a stage 1 safety phase by an independent committee, participants were recruited into stage 2 and randomized to either onabotulinumtoxinA 100, 300, 400, or 500 U, or placebo, all with hydrogel admixture. End points included change from baseline to week 12 in the number of urinary incontinence episodes (primary); micturition, urgency urinary, and nocturia episodes/day; volume voided per micturition; proportion of participants with a ≥50% decrease from baseline in urinary incontinence episodes/day; and Overactive Bladder Questionnaire total score. Adverse events were reported. RESULTS: Change from baseline to week 12 in number of urinary incontinence episodes was -2.72 with placebo and ranged from -0.89 to -1.85 in the onabotulinumtoxinA + hydrogel treatment groups. No difference from placebo was observed for any efficacy end point. The proportions of participants with treatment-emergent adverse events were similar among all groups, with asymptomatic bacteriuria the highest reported (6.7%-15.5%). There were no reports of urinary retention or elevated post-void residual volume. CONCLUSIONS: Intravesical instillation of an onabotulinumtoxinA + hydrogel admixture for the treatment of refractory overactive bladder was well tolerated, but it showed no improvement over placebo.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Chermansky CJ, Richter HE, Jacoby K, et al. Intravesical Instillation of OnabotulinumtoxinA in the Treatment of Refractory Overactive Bladder in Participants with Urinary Incontinence. J Urol. 2022. PMID: 35830550. doi:10.1097/JU.0000000000002800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。